{"title":"Manufacturing","authors":"E. Ruspini, P. Bonissone, W. Pedrycz","doi":"10.18356/c08601fa-en-fr","DOIUrl":null,"url":null,"abstract":": 1 SARS-CoV-2 may present risk to patients treated with donor-derived microbiome therapies 2 when lacking appropriate manufacturing controls and inactivation processes. We report that the 3 manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed 4 to reduce risk of Clostridioides difficile recurrence, inactivate Porcine Epidemic Diarrhea Virus, 5 a model coronavirus for SARS-CoV-2. 6","PeriodicalId":165433,"journal":{"name":"Handbook of Fuzzy Computation","volume":"306 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of Fuzzy Computation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18356/c08601fa-en-fr","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
: 1 SARS-CoV-2 may present risk to patients treated with donor-derived microbiome therapies 2 when lacking appropriate manufacturing controls and inactivation processes. We report that the 3 manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed 4 to reduce risk of Clostridioides difficile recurrence, inactivate Porcine Epidemic Diarrhea Virus, 5 a model coronavirus for SARS-CoV-2. 6
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
